Sreekumar Lab

Adaptive Glycan Remodeling in Cancer Progression

Dormancy in Breast Cancer


Journal article


Erica Dalla, Amulya Sreekumar, Julio A. Aguirre-Ghiso, Lewis A. Chodosh
Cold Spring Harbor Perspectives in Medicine, vol. 13, Cold Spring Harbor Laboratory, 2023 Apr, pp. a041331


Semantic Scholar DOI PubMedCentral PubMed
Cite

Cite

APA   Click to copy
Dalla, E., Sreekumar, A., Aguirre-Ghiso, J. A., & Chodosh, L. A. (2023). Dormancy in Breast Cancer. Cold Spring Harbor Perspectives in Medicine, 13, a041331. https://doi.org/10.1101/cshperspect.a041331


Chicago/Turabian   Click to copy
Dalla, Erica, Amulya Sreekumar, Julio A. Aguirre-Ghiso, and Lewis A. Chodosh. “Dormancy in Breast Cancer.” Cold Spring Harbor Perspectives in Medicine 13 (April 2023): a041331.


MLA   Click to copy
Dalla, Erica, et al. “Dormancy in Breast Cancer.” Cold Spring Harbor Perspectives in Medicine, vol. 13, Cold Spring Harbor Laboratory, Apr. 2023, p. a041331, doi:10.1101/cshperspect.a041331.


BibTeX   Click to copy

@article{dalla2023a,
  title = {Dormancy in Breast Cancer},
  year = {2023},
  month = apr,
  journal = {Cold Spring Harbor Perspectives in Medicine},
  pages = {a041331},
  publisher = {Cold Spring Harbor Laboratory},
  volume = {13},
  doi = {10.1101/cshperspect.a041331},
  author = {Dalla, Erica and Sreekumar, Amulya and Aguirre-Ghiso, Julio A. and Chodosh, Lewis A.},
  month_numeric = {4}
}

Abstract

The pattern of delayed recurrence in a subset of breast cancer patients has long been explained by a model that incorporates a variable period of cellular or tumor mass dormancy prior to disease relapse. In this review, we critically evaluate existing data to develop a framework for inferring the existence of dormancy in clinical contexts of breast cancer. We integrate these clinical data with rapidly evolving mechanistic insights into breast cancer dormancy derived from a broad array of genetically engineered mouse models as well as experimental models of metastasis. Finally, we propose actionable interventions and discuss ongoing clinical trials that translate the wealth of knowledge gained in the laboratory to the long-term clinical management of patients at a high risk of developing recurrence.